Pharvaris NV
PHVS25.120USD
+5.290+26.68%
收盘 07/11, 16:00（美东）报价延迟15分钟
1.37B总市值
亏损市盈率 TTM
关于 Pharvaris NV 公司
Pharvaris BV 是一家位于瑞士的临床阶段公司。该公司的业务重点是生产口服缓激肽 B2 受体拮抗剂，并正在开发针对所有亚型遗传性血管性水肿 (HAE) 的注射疗法的新替代品。
公司简介
公司代码PHVS
公司名称Pharvaris NV
上市日期Feb 05, 2021
成立日期2015
CEOMr. Berndt Modig, CPA
员工数量- -
证券类型Ordinary Share
年结日Feb 05
公司地址Emmy Noetherweg 2
城市LEIDEN
上市交易所NASDAQ Global Select Consolidated
国家Netherlands
邮编2333 BK
电话31712036410
网址https://pharvaris.com/
公司代码PHVS
上市日期Feb 05, 2021
成立日期2015
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月15日 周四
更新时间: 5月15日 周四
持股股东
股东类型
持股股东
持股股东
占比
General Atlantic LLC
13.82%
Fidelity Management & Research Company LLC
9.90%
Foresite Capital Management, LLC
8.09%
VenBio Partners LLC
7.87%
Viking Global Investors LP
6.70%
Other
53.61%
持股股东
持股股东
占比
General Atlantic LLC
13.82%
Fidelity Management & Research Company LLC
9.90%
Foresite Capital Management, LLC
8.09%
VenBio Partners LLC
7.87%
Viking Global Investors LP
6.70%
Other
53.61%
股东类型
持股股东
占比
Private Equity
30.24%
Investment Advisor
18.67%
Venture Capital
17.96%
Hedge Fund
15.17%
Investment Advisor/Hedge Fund
7.22%
Individual Investor
6.25%
Research Firm
0.15%
Bank and Trust
0.05%
Pension Fund
0.04%
Other
4.26%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
124
52.17M
95.74%
-1.39M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
2023Q1
61
28.67M
84.75%
-3.62M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
General Atlantic LLC
7.53M
13.82%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.40M
9.9%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
4.41M
8.09%
+12.70K
+0.29%
Mar 31, 2025
VenBio Partners LLC
4.29M
7.87%
--
--
Mar 31, 2025
Viking Global Investors LP
3.65M
6.7%
--
--
Mar 31, 2025
EQT Life Sciences
3.56M
6.53%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
6.06%
--
--
Mar 31, 2025
VR Adviser, LLC
3.11M
5.71%
-107.41K
-3.34%
Mar 31, 2025
Deerfield Management Company, L.P.
2.02M
3.7%
--
--
Mar 31, 2025
Commodore Capital LP
1.91M
3.51%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.96%
ALPS Medical Breakthroughs ETF
0.73%
iShares MSCI Netherlands ETF
0.1%
iShares MSCI Europe Small-Cap ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares MSCI EAFE Small-Cap ETF
0.01%
Avantis International Small Cap Equity ETF
0.01%
First Trust IPOX Europe Equity Opportunities ETF
0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.96%
ALPS Medical Breakthroughs ETF
占比0.73%
iShares MSCI Netherlands ETF
占比0.1%
iShares MSCI Europe Small-Cap ETF
占比0.02%
SPDR S&P International Small Cap ETF
占比0.02%
iShares MSCI EAFE Small-Cap ETF
占比0.01%
Avantis International Small Cap Equity ETF
占比0.01%
First Trust IPOX Europe Equity Opportunities ETF
占比0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
